zur Startseite


Veranstalter, Ort

Single-Agent Ibrutinib for Rituximab-Refractory Waldenström Macroglobulinemia: Final Analysis of the Substudy of the Phase III Innovate Trial

Judith Trotman, Christian Buske, Alessandra Tedeschi, Jeffrey V Matous, David MacDonald, Constantine S Tam, Olivier Tournilhac, Shuo Ma, Steven P Treon, Albert Oriol, Jerry Ping, Eva M Briso, Israel Arango-Hisijara, Meletios A Dimopoulos
read more ›

Targeting of CXCR4 by the Naturally Occurring CXCR4 Antagonist EPI-X4 in Waldenström's Macroglobulinemia

Lisa Marie Kaiser, Mirja Harms, Daniel Sauter, Vijay P S Rawat, Mirco Glitscher, Eberhard Hildt, Daniel Tews, Zachary Hunter, Jan Münch, Christian Buske
read more ›


Presentations on WM at this year‘s ASH 2013 in New Orleans

from our consortium on:

  • Elevated Von Willebrand Factor Antigen Serum Levels and their association with poor prognosis In patients with symptomatic Waldenstrom’s Macroglobulinemia  (Efstathios Kastritis et al., Athens, Greece)
  • Disease unrelated mortality accounting for differences in survival in patients >75 Years with symptomatic Waldenström’s Macroglobulinemia  (Efstathios Kastritis et al., Athens, Greece)
  • Newest update of the WM2 trial on the efficacy of Bortezomib in patients with advanced Waldenström Macroglobulinemia  (V. Leblond et al., Paris, France)
‹ back